Innoviva ROE 2006-2020 | INVA

Current and historical return on equity (ROE) values for Innoviva (INVA) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Innoviva ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2020-06-30 $0.23B $0.49B 59.80%
2020-03-31 $0.19B $0.41B 59.11%
2019-12-31 $0.16B $0.34B 58.90%
2019-09-30 $0.38B $0.28B 168.99%
2019-06-30 $0.38B $0.25B 307.63%
2019-03-31 $0.40B $0.20B 1666.67%
2018-12-31 $0.40B $0.16B -499.68%
2018-09-30 $0.19B $-0.11B -105.70%
2018-06-30 $0.17B $-0.16B -80.10%
2018-03-31 $0.15B $-0.21B -60.25%
2017-12-31 $0.13B $-0.24B -48.86%
2017-09-30 $0.10B $-0.22B -33.47%
2017-06-30 $0.09B $-0.30B -27.22%
2017-03-31 $0.07B $-0.33B -20.31%
2016-12-31 $0.06B $-0.35B -16.32%
2016-09-30 $0.04B $-0.37B -10.58%
2016-06-30 $0.02B $-0.36B -5.18%
2016-03-31 $-0.01B $-0.36B 1.51%
2015-12-31 $-0.02B $-0.34B 6.56%
2015-09-30 $-0.04B $-0.32B 14.55%
2015-06-30 $-0.06B $-0.29B 23.09%
2015-03-31 $-0.11B $-0.26B 51.85%
2014-12-31 $-0.17B $-0.22B 198.24%
2014-09-30 $-0.20B $-0.19B -448.62%
2014-06-30 $-0.23B $-0.19B -130.11%
2014-03-31 $-0.20B $0.26B -82.21%
2013-12-31 $-0.17B $0.30B -84.26%
2013-09-30 $-0.15B $0.33B -91.10%
2013-06-30 $-0.14B $0.09B -109.88%
2013-03-31 $-0.14B $0.09B -91.95%
2012-12-31 $-0.02B $0.16B -13.77%
2012-09-30 $-0.02B $0.17B -34.16%
2012-06-30 $-0.02B $0.19B -163.27%
2012-03-31 $-0.01B $0.01B 18.08%
2011-12-31 $-0.12B $-0.09B 219.91%
2011-09-30 $-0.10B $-0.06B 268.49%
2011-06-30 $-0.09B $-0.04B 154.39%
2011-03-31 $-0.08B $-0.03B 105.99%
2010-12-31 $-0.08B $-0.02B 83.58%
2010-09-30 $-0.09B $-0.14B 61.16%
2010-06-30 $-0.09B $-0.13B 58.37%
2010-03-31 $-0.09B $-0.11B 55.97%
2009-12-31 $-0.09B $-0.19B 50.97%
2009-09-30 $-0.08B $-0.18B 51.55%
2009-06-30 $-0.08B $-0.16B 55.42%
2009-03-31 $-0.08B $-0.14B 64.34%
2008-12-31 $-0.09B $-0.14B 81.21%
2008-09-30 $-0.11B $-0.13B 112.69%
2008-06-30 $-0.12B $-0.11B 157.42%
2008-03-31 $-0.14B $-0.09B 261.68%
2007-12-31 $-0.16B $-0.07B 617.48%
2007-09-30 $-0.16B $-0.04B -2523.08%
2007-06-30 $-0.17B $-0.02B -422.36%
2007-03-31 $-0.17B $0.02B -219.14%
2006-12-31 $-0.17B $0.06B -150.57%
2006-09-30 $-0.17B $0.09B -155.25%
2006-06-30 $-0.17B $0.13B -153.85%
2006-03-31 $-0.16B $0.16B -143.11%
2005-12-31 $-0.14B $0.06B -126.27%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.376B $0.261B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $389.737B 18.57
Roche Holding AG (RHHBY) Switzerland $293.115B 0.00
Pfizer (PFE) United States $213.329B 13.33
Merck (MRK) United States $204.641B 14.60
Novartis AG (NVS) Switzerland $188.566B 14.66
AbbVie (ABBV) United States $163.035B 9.93
Novo Nordisk (NVO) Denmark $152.167B 24.76
Eli Lilly (LLY) United States $146.340B 22.34
AstraZeneca (AZN) United Kingdom $145.338B 28.25
Sanofi (SNY) $127.486B 15.15
GlaxoSmithKline (GSK) United Kingdom $102.699B 13.47
Bayer (BAYRY) Germany $61.996B 8.94
H Lundbeck (HLUYY) Denmark $7.388B 12.84